OP-9 Assessing the Burden and Budget Impacts of HCV Elimination Strategies in Uruguay Using Decision-Analytic Modeling

Conflict of interest: Yes, Coalition For Global Hepatitis Elimination support the project Introduction and Objectives: Background: WHO aims for HCV elimination by 2030, targeting a 80% reduction in incidence and a 65% reduction in mortality, with 90% diagnosed and 80% treatment coverage compared to...

Full description

Saved in:
Bibliographic Details
Main Authors: Victoria Mainardi Rial, Daniela Olivari, Solange Gerona, Alec Aron, Huaiyang Zhong, Jagpreet Chhatwal, Lindsey Hiebert, John Ward
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Annals of Hepatology
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268124003909
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850112136106213376
author Victoria Mainardi Rial
Daniela Olivari
Solange Gerona
Alec Aron
Huaiyang Zhong
Jagpreet Chhatwal
Lindsey Hiebert
John Ward
author_facet Victoria Mainardi Rial
Daniela Olivari
Solange Gerona
Alec Aron
Huaiyang Zhong
Jagpreet Chhatwal
Lindsey Hiebert
John Ward
author_sort Victoria Mainardi Rial
collection DOAJ
description Conflict of interest: Yes, Coalition For Global Hepatitis Elimination support the project Introduction and Objectives: Background: WHO aims for HCV elimination by 2030, targeting a 80% reduction in incidence and a 65% reduction in mortality, with 90% diagnosed and 80% treatment coverage compared to 2015. Uruguay, with a population of 3.4 million, has low HCV prevalence and universal treatment access, but testing and treatment rates are low. Objective: To assess the feasibility of HCV elimination and compare the burden and budget impacts of various testing strategies in Uruguay. Patients / Materials and Methods: Methods: Disease burden and budget impact projections were generated using a decision-analytic model, The Hep C Elimination Tool, developed by Massachusetts General Hospital with support from the Coalition for Global Hepatitis Elimination and calibrated with Uruguayan parameters. Results and Discussion: With 100% follow-up for confirmatory testing and treatment initiation, 42 strategies meet three elimination goals by 2030.The strategy with the greatest death reductionuses a 30% annual screening rate and 80% treatment rate, requiring 3,220,000 people to be tested (800,000/annual from 2024-2026) and 20,000 treated (5,000/annual from 2024-2026) by 2030. This achieves 91% diagnosis and treatment coverage, with reductions in incidence of 89%, prevalence of 91%, decompensated cirrhosis of 74%, HCC of 46% and mortality of 56%, costing $121.63 million from 2022-2050.The most gradual strategy uses a 15% annual screening rate and 70% treatment rate, requiring 3,190,000 people to be tested (400,000/annual from 2023-2029) and 19,035 treated (2,500/annual from 2024-2029) by 2030. This achieves 90% diagnosis and 85% treatment coverage, with reductions in incidence of 82%, prevalence of 85%, decompensated cirrhosis of 66%, HCC of 34% and mortality of 30%, costing $132.92 million from 2022-2050. Conclusions: Uruguay can achieve WHO HCV elimination incidence goal and diagnosis and treatment targets by 2030. Mathematical modeling can inform policymakers about the impact of different interventions on HCV burden, supporting informed and cost-effective decision-making.
format Article
id doaj-art-00d8235dba1f40088a43e5320511a1b7
institution OA Journals
issn 1665-2681
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Annals of Hepatology
spelling doaj-art-00d8235dba1f40088a43e5320511a1b72025-08-20T02:37:28ZengElsevierAnnals of Hepatology1665-26812024-12-012910160710.1016/j.aohep.2024.101607OP-9 Assessing the Burden and Budget Impacts of HCV Elimination Strategies in Uruguay Using Decision-Analytic ModelingVictoria Mainardi Rial0Daniela Olivari1Solange Gerona2Alec Aron3Huaiyang Zhong4Jagpreet Chhatwal5Lindsey Hiebert6John Ward7Programa Nacional de Trasplante Hepático URUGUAY, Montevideo, UruguayPrograma Nacional de Trasplante Hepático URUGUAY, Montevideo, UruguayPrograma Nacional de Trasplante Hepático URUGUAY, Montevideo, UruguayMassachusetts General Hospital Institute for Technology Assessment, Boston, Estados Unidos (EEUU)Massachusetts General Hospital Institute for Technology Assessment, Boston, Estados Unidos (EEUU)Massachusetts General Hospital Institute for Technology Assessment, Boston, Estados Unidos (EEUU)Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, Estados Unidos (EEUU)Coalition for Global Hepatitis Elimination, Task Force for Global Health, Decatur, Estados Unidos (EEUU)Conflict of interest: Yes, Coalition For Global Hepatitis Elimination support the project Introduction and Objectives: Background: WHO aims for HCV elimination by 2030, targeting a 80% reduction in incidence and a 65% reduction in mortality, with 90% diagnosed and 80% treatment coverage compared to 2015. Uruguay, with a population of 3.4 million, has low HCV prevalence and universal treatment access, but testing and treatment rates are low. Objective: To assess the feasibility of HCV elimination and compare the burden and budget impacts of various testing strategies in Uruguay. Patients / Materials and Methods: Methods: Disease burden and budget impact projections were generated using a decision-analytic model, The Hep C Elimination Tool, developed by Massachusetts General Hospital with support from the Coalition for Global Hepatitis Elimination and calibrated with Uruguayan parameters. Results and Discussion: With 100% follow-up for confirmatory testing and treatment initiation, 42 strategies meet three elimination goals by 2030.The strategy with the greatest death reductionuses a 30% annual screening rate and 80% treatment rate, requiring 3,220,000 people to be tested (800,000/annual from 2024-2026) and 20,000 treated (5,000/annual from 2024-2026) by 2030. This achieves 91% diagnosis and treatment coverage, with reductions in incidence of 89%, prevalence of 91%, decompensated cirrhosis of 74%, HCC of 46% and mortality of 56%, costing $121.63 million from 2022-2050.The most gradual strategy uses a 15% annual screening rate and 70% treatment rate, requiring 3,190,000 people to be tested (400,000/annual from 2023-2029) and 19,035 treated (2,500/annual from 2024-2029) by 2030. This achieves 90% diagnosis and 85% treatment coverage, with reductions in incidence of 82%, prevalence of 85%, decompensated cirrhosis of 66%, HCC of 34% and mortality of 30%, costing $132.92 million from 2022-2050. Conclusions: Uruguay can achieve WHO HCV elimination incidence goal and diagnosis and treatment targets by 2030. Mathematical modeling can inform policymakers about the impact of different interventions on HCV burden, supporting informed and cost-effective decision-making.http://www.sciencedirect.com/science/article/pii/S1665268124003909
spellingShingle Victoria Mainardi Rial
Daniela Olivari
Solange Gerona
Alec Aron
Huaiyang Zhong
Jagpreet Chhatwal
Lindsey Hiebert
John Ward
OP-9 Assessing the Burden and Budget Impacts of HCV Elimination Strategies in Uruguay Using Decision-Analytic Modeling
Annals of Hepatology
title OP-9 Assessing the Burden and Budget Impacts of HCV Elimination Strategies in Uruguay Using Decision-Analytic Modeling
title_full OP-9 Assessing the Burden and Budget Impacts of HCV Elimination Strategies in Uruguay Using Decision-Analytic Modeling
title_fullStr OP-9 Assessing the Burden and Budget Impacts of HCV Elimination Strategies in Uruguay Using Decision-Analytic Modeling
title_full_unstemmed OP-9 Assessing the Burden and Budget Impacts of HCV Elimination Strategies in Uruguay Using Decision-Analytic Modeling
title_short OP-9 Assessing the Burden and Budget Impacts of HCV Elimination Strategies in Uruguay Using Decision-Analytic Modeling
title_sort op 9 assessing the burden and budget impacts of hcv elimination strategies in uruguay using decision analytic modeling
url http://www.sciencedirect.com/science/article/pii/S1665268124003909
work_keys_str_mv AT victoriamainardirial op9assessingtheburdenandbudgetimpactsofhcveliminationstrategiesinuruguayusingdecisionanalyticmodeling
AT danielaolivari op9assessingtheburdenandbudgetimpactsofhcveliminationstrategiesinuruguayusingdecisionanalyticmodeling
AT solangegerona op9assessingtheburdenandbudgetimpactsofhcveliminationstrategiesinuruguayusingdecisionanalyticmodeling
AT alecaron op9assessingtheburdenandbudgetimpactsofhcveliminationstrategiesinuruguayusingdecisionanalyticmodeling
AT huaiyangzhong op9assessingtheburdenandbudgetimpactsofhcveliminationstrategiesinuruguayusingdecisionanalyticmodeling
AT jagpreetchhatwal op9assessingtheburdenandbudgetimpactsofhcveliminationstrategiesinuruguayusingdecisionanalyticmodeling
AT lindseyhiebert op9assessingtheburdenandbudgetimpactsofhcveliminationstrategiesinuruguayusingdecisionanalyticmodeling
AT johnward op9assessingtheburdenandbudgetimpactsofhcveliminationstrategiesinuruguayusingdecisionanalyticmodeling